Ashley E Ross, Jingbin Zhang, Huei-Chung Huang, Rikiya Yamashita, Jessica Keim-Malpass, Jeffry P Simko, Sandy DeVries, Todd M Morgan, Luis Souhami, Michael C Dobelbower, L Scott McGinnis, Christopher U Jones, Robert T Dess, Kenneth L Zeitzer, Kwang Choi, Alan C Hartford, Jeff M Michalski, Adam Raben, Leonard G Gomella, A Oliver Sartor, Seth A Rosenthal, Howard M Sandler, Daniel E Spratt, Stephanie L Pugh, Osama Mohamad, Andre Esteva, Emmalyn Chen, Edward M Schaeffer, Phuoc T Tran, Felix Y Feng
BACKGROUND: Accurate risk stratification is critical to guide management decisions in localized prostate cancer (PCa). Previously, we had developed and validated a multimodal artificial intelligence (MMAI) model generated from digital histopathology and clinical features. Here, we externally validate this model on men with high-risk or locally advanced PCa treated and followed as part of a phase 3 randomized control trial. OBJECTIVE: To externally validate the MMAI model on men with high-risk or locally advanced PCa treated and followed as part of a phase 3 randomized control trial...
January 31, 2024: European Urology Oncology